Target-Based Whole-Cell Screening by 1H NMR Spectroscopy

被引:16
作者
Ma, Junhe [1 ]
Cao, Qing [1 ]
McLeod, Sarah M. [2 ]
Ferguson, Keith [2 ]
Gao, Ning [1 ]
Breeze, Alexander L. [3 ]
Hu, Jun [1 ]
机构
[1] AstraZeneca R&D Boston, Discovery Sci, Waltham, MA 02451 USA
[2] AstraZeneca R&D Boston, Infect Innovat Med, Waltham, MA 02451 USA
[3] AstraZeneca R&D, Discovery Sci, Macclesfield SK10 4TG, Cheshire, England
关键词
drug discovery; invivo methods; New Delhi metallo--lactamase; NMR spectroscopy; whole-cell screening; BETA-LACTAMASE INHIBITORS; DRUG DISCOVERY;
D O I
10.1002/anie.201410701
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
An NMR-based approach marries the two traditional screening technologies (phenotypic and target-based screening) to find compounds inhibiting a specific enzymatic reaction in bacterial cells. Building on a previous study in which it was demonstrated that hydrolytic decomposition of meropenem in living Escherichia coli cells carrying New Delhi metallo--lactamase subclass 1 (NDM-1) can be monitored in real time by NMR spectroscopy, we designed a cell-based NMR screening platform. A strong NDM-1 inhibitor was identified with cellular IC50 of 0.51M, which is over 300-fold more potent than captopril, a known NDM-1 inhibitor. This new screening approach has great potential to be applied to targets in other cell types, such as mammalian cells, and to targets that are only stable or functionally competent in the cellular environment.
引用
收藏
页码:4764 / 4767
页数:4
相关论文
共 23 条
  • [1] Pathway-Selective Sensitization of Mycobacterium tuberculosis for Target-Based Whole-Cell Screening
    Abrahams, Garth L.
    Kumar, Anuradha
    Savvi, Suzana
    Hung, Alvin W.
    Wen, Shijun
    Abell, Chris
    Barry, Clifton E., III
    Sherman, David R.
    Boshoff, Helena I. M.
    Mizrahi, Valerie
    [J]. CHEMISTRY & BIOLOGY, 2012, 19 (07): : 844 - 854
  • [2] NMR Screening and Hit Validation in Fragment Based Drug Discovery
    Campos-Olivas, Ramon
    [J]. CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2011, 11 (01) : 43 - 67
  • [3] Metallo-β-lactamases: a last frontier for β-lactams?
    Cornaglia, Giuseppe
    Giamarellou, Helen
    Rossolini, Gian Maria
    [J]. LANCET INFECTIOUS DISEASES, 2011, 11 (05) : 381 - 393
  • [4] An array of target-specific screening strains for antibacterial discovery
    DeVito, JA
    Mills, JA
    Liu, VG
    Agarwal, A
    Sizemore, CF
    Yao, ZJ
    Stoughton, DM
    Cappiello, MG
    Barbosa, MDFS
    Foster, LA
    Pompliano, DL
    [J]. NATURE BIOTECHNOLOGY, 2002, 20 (05) : 478 - 483
  • [5] Three Decades of β-Lactamase Inhibitors
    Drawz, Sarah M.
    Bonomo, Robert A.
    [J]. CLINICAL MICROBIOLOGY REVIEWS, 2010, 23 (01) : 160 - +
  • [6] Genomic sciences and the medicine of tomorrow
    Drews, J
    [J]. NATURE BIOTECHNOLOGY, 1996, 14 (11) : 1516 - &
  • [7] Recent Advances in the Discovery of Metallo-β-Lactamase Inhibitors for β-lactam Antibiotic-Resistant Reversing Agents
    Guo, Zhenzhen
    Ma, Shutao
    [J]. CURRENT DRUG TARGETS, 2014, 15 (07) : 689 - 702
  • [8] The druggable genome
    Hopkins, AL
    Groom, CR
    [J]. NATURE REVIEWS DRUG DISCOVERY, 2002, 1 (09) : 727 - 730
  • [9] Kotz J, 2012, Science-Business eXchange, V5, DOI DOI 10.1038/SCIBX.2012.380
  • [10] Theory and applications of NMR-based screening in pharmaceutical research
    Lepre, CA
    Moore, JM
    Peng, JW
    [J]. CHEMICAL REVIEWS, 2004, 104 (08) : 3641 - 3675